PRALSETINIB for Lung neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 517 adverse event reports in the FDA FAERS database where PRALSETINIB was used for Lung neoplasm malignant.
Most Reported Side Effects for PRALSETINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 126 | 8.9% | 126 | 8 |
| Fatigue | 104 | 7.3% | 5 | 19 |
| Asthenia | 96 | 6.8% | 11 | 33 |
| Off label use | 92 | 6.5% | 12 | 16 |
| Hypertension | 89 | 6.3% | 10 | 23 |
| Disease progression | 85 | 6.0% | 54 | 23 |
| Anaemia | 80 | 5.6% | 3 | 37 |
| Diarrhoea | 79 | 5.6% | 7 | 31 |
| Pyrexia | 75 | 5.3% | 7 | 47 |
| White blood cell count decreased | 74 | 5.2% | 4 | 31 |
| Blood pressure increased | 73 | 5.1% | 3 | 23 |
| Constipation | 72 | 5.1% | 3 | 23 |
| Pneumonia | 62 | 4.4% | 12 | 46 |
| Platelet count decreased | 50 | 3.5% | 3 | 24 |
| No adverse event | 46 | 3.2% | 0 | 0 |
Other Indications for PRALSETINIB
Non-small cell lung cancer (270)
Thyroid cancer (199)
Product used for unknown indication (152)
Medullary thyroid cancer (48)
Lung adenocarcinoma (38)
Non-small cell lung cancer metastatic (31)
Bronchial carcinoma (17)
Thyroid cancer metastatic (17)
Lung adenocarcinoma stage iv (15)
Lung carcinoma cell type unspecified stage 0 (15)
Other Drugs Used for Lung neoplasm malignant
ERLOTINIB (9,207)
OSIMERTINIB (4,754)
NIVOLUMAB (4,197)
PEMBROLIZUMAB (3,575)
CARBOPLATIN (3,487)
ALECTINIB (2,932)
PEMETREXED (2,422)
CRIZOTINIB (1,949)
BEVACIZUMAB (1,810)
PACLITAXEL (1,747)